Evidence map›Paper›PMID 25491299›Full record

Trial reportInvestigative ophthalmology & visual science2014

Intravitreal autologous bone marrow CD34+ cell therapy for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trial findings.

Susanna S Park, Gerhard Bauer, Mehrdad Abedi, Suzanne Pontow, Athanasios Panorgias, Ravi Jonnal, Robert J Zawadzki, John S Werner, Jan Nolta

2 registry-linked trialsAbstract readClinical Trial, Phase IRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Investigative ophthalmology & visual science, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 96 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
96citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01736059 phase1active not recruitingnot on this map

A Pilot Clinical Trial of the Feasibility and Safety of Intravitreal Autologous Adult Bone Marrow Stem Cells in Treating Eyes With Vision Loss From Retinopathy

TypeinterventionalSponsorUniversity of California, DavisRan2012 to 2026Enrolled15ConditionsNon-exudative Age-related Macular Degeneration, Diabetic Retinopathy, Retina Vein Occlusion, Retinitis PigmentosaArmsCD34+ bone marrow stem cells intravitreal
NCT03981549 phase1 / phase2completednot on this mapstarted 2019, after this paper: background citation

Phase I/II Randomized, Prospective, Double-masked, Sham-controlled Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Central Retinal Vein Occlusion

TypeinterventionalSponsorThe Emmes Company, LLCRan2019 to 2023Enrolled16ConditionsCentral Retinal Vein OcclusionArmsAutologous Bone Marrow CD34+ Stem Cells, Sham Therapy
3 · Its place in the literature

Who cites it

96 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Rekindling Vision: Innovative Strategies for Treating Retinal Degeneration.International journal of molecular sciences · 2025
    Review
  17. Article
  18. Review
  19. Review
  20. Article

36 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Susanna S ParkDepartment of Ophthalmology and Vision Science, University of California-Davis Eye Center, Sacramento, California, United States.
Gerhard BauerInstitute for Regenerative Cures, University of California-Davis School of Medicine, Sacramento, California, United States.
Mehrdad AbediDivision of Hematology and Oncology, University of California-Davis Cancer Center, Sacramento, California, United States.
Suzanne PontowInstitute for Regenerative Cures, University of California-Davis School of Medicine, Sacramento, California, United States.
Athanasios PanorgiasDepartment of Ophthalmology and Vision Science, University of California-Davis Eye Center, Sacramento, California, United States.
Ravi JonnalDepartment of Ophthalmology and Vision Science, University of California-Davis Eye Center, Sacramento, California, United States.
Robert J ZawadzkiDepartment of Ophthalmology and Vision Science, University of California-Davis Eye Center, Sacramento, California, United States.
John S WernerDepartment of Ophthalmology and Vision Science, University of California-Davis Eye Center, Sacramento, California, United States.
Jan NoltaInstitute for Regenerative Cures, University of California-Davis School of Medicine, Sacramento, California, United States.

Funding

VISION RESEARCH CORE GRANTP30EY012576 · NEI · UNIVERSITY OF CALIFORNIA DAVIS · PI LISA M OAKES · 1999 to 2026
$18.9M
Structure and Function of the Chorioretinal Complex in Age-Related Macular DegeneR01EY024239 · NEI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI WERNER, JOHN S · 2014 to 2018
$2.4M
NEI NIH HHS EY024239NEI NIH HHS P30 EY012576NEI NIH HHS R01 EY024239
6 · The paper itself

Abstract

purposeBecause human bone marrow (BM) CD34+ stem cells home into damaged tissue and may play an important role in tissue repair, this pilot clinical trial explored the safety and feasibility of intravitreal autologous CD34+ BM cells as potential therapy for ischemic or degenerative retinal conditions.

methodsThis prospective study enrolled six subjects (six eyes) with irreversible vision loss from retinal vascular occlusion, hereditary or nonexudative age-related macular degeneration, or retinitis pigmentosa. CD34+ cells were isolated under Good Manufacturing Practice conditions from the mononuclear cellular fraction of the BM aspirate using a CliniMACs magnetic cell sorter. After intravitreal CD34+ cell injection, serial ophthalmic examinations, microperimetry/perimetry, fluorescein angiography, electroretinography (ERG), optical coherence tomography (OCT), and adaptive optics OCT were performed during the 6-month follow-up.

resultsA mean of 3.4 million (range, 1-7 million) CD34+ cells were isolated and injected per eye. The therapy was well tolerated with no intraocular inflammation or hyperproliferation. Best-corrected visual acuity and full-field ERG showed no worsening after 6 months. Clinical examination also showed no worsening during follow-up except among age-related macular degeneration subjects in whom mild progression of geographic atrophy was noted in both the study eye and contralateral eye at 6-month follow-up, concurrent with some possible decline on multifocal ERG and microperimetry. Cellular in vivo imaging using adaptive optics OCT showed changes suggestive of new cellular incorporation into the macula of the hereditary macular degeneration study eye.

conclusionsIntravitreal autologous BM CD34+ cell therapy appears feasible and well tolerated in eyes with ischemic or degenerative retinal conditions and merits further exploration. (ClinicalTrials.gov number, NCT01736059.).

Indexed as

AdultAgedAged, 80 and overAntigens, CD34Bone Marrow CellsCell TransplantationFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansIntravitreal InjectionsIschemiaMaleProspective StudiesRetinal DegenerationAntigens, CD34OCTretinal degenerationretinal imagingretinal vein occlusionstem cells

Identifiers

PMID25491299
PMCPMC4288143

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.